Most Read News

Trump is contemplating further tariffs on China and intends to put tariffs on Canada and Mexico on Saturday.

The company’s net interest income (NII) witnessed a growth of 2.8% y-o-y to ₹11,417 Crore against ₹11,101 Crore in Q3FY25.

However, despite excellent performance during the quarter, EBITDA margins declined to 6% in Q3FY25, against 7.1% in Q3FY24.

The company’s revenue for the quarter under review witnessed a growth of 17% y-o-y to ₹4,443 Crore.

The company registered a 28% increase in its December quarter’s Asset Under Management (AUM) at ₹3,98,043 Crore.

Revenue from operations was at ₹34,253.52 crore, which was 8% QoQ growth on the back of higher gas demand, against ₹31,822.62 crore in the preceding quarter

Biocon's EBITDA increased by 16% YoY to ₹787 crore, which shows improved operational performance.

The company’s revenue for the quarter registered an increase of 116% y-o-y to ₹3,457 Crore as compared to ₹1,596 Crore.

Revenue grew 7% year over year to ₹3,255 crore, as compared with ₹3,043 crore during the same quarter of last fiscal year

EBITDA grew 48% YoY at ₹210 crore, from ₹142 crore in the same quarter last year, marking better profitability.